<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/21/379j–11" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/21/379j–11/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/21/379j–11/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_379j_11"><akn:num>379j–11</akn:num><akn:heading>Definitions</akn:heading><akn:content><akn:p>§ 379j–11. Definitions
For purposes of this subpart:(1)(A) The term “animal drug application” means—(i) an application for approval of any new animal drug submitted under section 360b(b)(1) of this title; or

(ii) an application for conditional approval of a new animal drug submitted under section 360ccc of this title.


(B) Such term does not include either a new animal drug application submitted under section 360b(b)(2) of this title or a supplemental animal drug application.


(2) The term “supplemental animal drug application” means—(A) a request to the Secretary to approve a change in an animal drug application which has been approved; or

(B) a request to the Secretary to approve a change to an application approved under section 360b(c)(2) of this title for which data with respect to safety or effectiveness are required.


(3) The term “animal drug product” means each specific strength or potency of a particular active ingredient or ingredients in final dosage form marketed by a particular manufacturer or distributor, which is uniquely identified by the labeler code and product code portions of the National Drug Code, and for which an animal drug application or a supplemental animal drug application has been approved.

(4) The term “animal drug establishment” means a foreign or domestic place of business which is at one general physical location consisting of one or more buildings all of which are within 5 miles of each other, at which one or more animal drug products are manufactured in final dosage form.

(5) The term “investigational animal drug submission” means—(A) the filing of a claim for an investigational exemption under section 360b(j) of this title for a new animal drug intended to be the subject of an animal drug application or a supplemental animal drug application; or

(B) the submission of information for the purpose of enabling the Secretary to evaluate the safety or effectiveness of an animal drug application or supplemental animal drug applic</akn:p></akn:content><akn:subsection eId="subsec_379j_11_1"><akn:num>(1)</akn:num><akn:content><akn:p>(1)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_2"><akn:num>(2)</akn:num><akn:content><akn:p>(2) The term “supplemental animal drug application” means—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_3"><akn:num>(3)</akn:num><akn:content><akn:p>(3) The term “animal drug product” means each specific strength or potency of a particular active ingredient or ingredients in final dosage form marketed by a particular manufacturer or distributor, which is uniquely identified by the labeler code and product code portions of the National Drug Code, and for which an animal drug application or a supplemental animal drug application has been approved.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_4"><akn:num>(4)</akn:num><akn:content><akn:p>(4) The term “animal drug establishment” means a foreign or domestic place of business which is at one general physical location consisting of one or more buildings all of which are within 5 miles of each other, at which one or more animal drug products are manufactured in final dosage form.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_5"><akn:num>(5)</akn:num><akn:content><akn:p>(5) The term “investigational animal drug submission” means—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_6"><akn:num>(6)</akn:num><akn:content><akn:p>(6) The term “animal drug sponsor” means either an applicant named in an animal drug application that has not been withdrawn by the applicant and for which approval has not been withdrawn by the Secretary, or a person who has submitted an investigational animal drug submission that has not been terminated or otherwise rendered inactive by the Secretary.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_7"><akn:num>(7)</akn:num><akn:content><akn:p>(7) The term “final dosage form” means, with respect to an animal drug product, a finished dosage form which is approved for administration to an animal without substantial further manufacturing. Such term includes animal drug products intended for mixing in animal feeds.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_8"><akn:num>(8)</akn:num><akn:content><akn:p>(8) The term “process for the review of animal drug applications” means the following activities of the Secretary with respect to the review of animal drug applications, supplemental animal drug applications, and investigational animal drug submissions:</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_9"><akn:num>(9)</akn:num><akn:content><akn:p>(9) The term “costs of resources allocated for the process for the review of animal drug applications” means the expenses in connection with the process for the review of animal drug applications for—</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_379j_11_10"><akn:num>(10)</akn:num><akn:content><akn:p>(10) The term “adjustment factor” applicable to a fiscal year refers to the formula set forth in section 379g(8) of this title with the base or comparator month being October 2002.</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>